So there really is an active ingredient, but again, they haven’t been evaluated for their efficacy or safety.” But not all ...

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...

This product contains Bimatoprost, a medication used to treat ocular conditions such as glaucoma. It moved into the cosmetics space once people realised it also increased the size and length of ...

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle ...